Erbitux Injection 100mg

About Erbitux Injection 100mg

Erbitux Injection 100mg Uses

• Treating metastatic colorectal cancer that has spread to other parts of the body, usually alongside chemotherapy.
• Treating RAS wild type colorectal cancer as a single agent when earlier chemotherapy is no longer effective.
• Treating locally advanced squamous cell cancer of the head and neck, combined with radiation therapy.
• Treating recurrent or metastatic head and neck cancer, combined with platinum based chemotherapy.
• Slowing tumor growth by blocking a receptor that many cancer cells depend on to grow and divide.

Erbitux Injection 100mg Benefits

• Targets cancer cells more precisely than standard chemotherapy alone, sparing some healthy tissue.
• Improves response rates when combined with chemotherapy in eligible colorectal cancer patients.
• Extends progression free survival in several head and neck cancer treatment protocols.
• Works through a well studied mechanism that oncologists can track with routine blood tests.
• Offers an additional treatment option for patients whose tumors express the EGFR receptor.

Erbitux injection 100mg is not a medicine anyone picks up from a local chemist. It is a chemotherapy grade biologic that is prepared and given only inside a hospital or a certified oncology day care unit, under the direct supervision of a cancer specialist. Patients in Lahore, Karachi, Islamabad, and Rawalpindi typically receive this infusion at major cancer hospitals and oncology clinics that have trained staff and emergency support on site. The drug is delivered slowly through a vein over one to two hours, and patients are watched closely during and after the infusion for any reaction. Oladoc helps patients across these cities find qualified oncologists and connect with hospitals that offer Erbitux based cancer treatment, so families can plan visits, transport, and follow up care around a proper treatment schedule instead of searching for the injection on their own.

Erbitux contains cetuximab, a lab made antibody that attaches to a protein called EGFR on the surface of certain cancer cells. Many colorectal and head and neck tumors depend on this protein to keep growing and spreading, so blocking it can slow the disease down. Before starting treatment, doctors in Pakistan usually order tumor tissue testing to check the RAS gene status, because this medicine does not work and may even be harmful in tumors with certain RAS mutations. This step is a routine part of cancer care and is not something patients can skip or self assess. Once testing confirms a patient is a suitable candidate, the oncology team plans a dosing schedule that often runs on a weekly or every two week basis, paired with chemotherapy or radiation depending on the type and stage of cancer being treated.

Because Erbitux can trigger serious infusion reactions, including some that affect breathing and heart rhythm, it is always given with pre medication and close monitoring in a clinical setting. Nursing staff track blood pressure, oxygen levels, and general comfort throughout the infusion, and patients are usually asked to stay for observation afterward. Skin reactions such as an acne like rash are common and are usually managed with specific creams or dose adjustments rather than stopping treatment altogether. Anyone considering this therapy should discuss their full medical history, including heart or lung conditions, with their oncologist before the first dose. Regular blood tests are also needed during treatment to check magnesium and other electrolyte levels, since this medicine can lower them over time. Working with an experienced cancer care team keeps these risks manageable and allows problems to be caught early.

Drug Class

• Epidermal growth factor receptor (EGFR) inhibitor
• Chimeric monoclonal antibody
• Targeted anti-cancer biologic therapy
• Used in combination with chemotherapy or radiation protocols

Erbitux Injection 100mg formula

• Cetuximab

Available forms

• Injection

How to use Erbitux Injection 100mg?

• Given only by a doctor or trained oncology nurse inside a hospital or infusion center, never self-administered at home.
• Delivered as a slow intravenous infusion through a vein, usually over sixty to one hundred twenty minutes.
• An antihistamine is given before the first dose to lower the chance of an infusion reaction.
• Dosing schedule and infusion speed are set by the oncologist based on body surface area and treatment protocol.
• Patients are monitored for at least one hour after the infusion ends before being allowed to leave the clinic.

Drug Interactions

Erbitux is usually combined with other cancer treatments under close medical supervision, and certain combinations need extra caution.

• Radiation therapy with platinum based chemotherapy: Combining Erbitux with radiation and platinum drugs for head and neck cancer raises the risk of serious heart and lung side effects, so this combination is only used with careful monitoring.
• Irinotecan based chemotherapy: Adding Erbitux to irinotecan containing regimens can increase the chance of severe diarrhea, which the care team manages with supportive medicines.
• Live vaccines: Vaccination during Erbitux treatment should be discussed with the oncologist first, since the safety of live vaccines during cancer therapy is not well established.
• Other EGFR targeted drugs: Combining Erbitux with other EGFR inhibitors is generally avoided unless specifically directed by a cancer specialist, since this can increase toxicity without added benefit.

Risks and warnings

• Severe infusion reactions: This medicine can cause serious allergic reactions during or shortly after the infusion, including difficulty breathing and a sudden drop in blood pressure, which is why it is only given where emergency care is available.
• Cardiopulmonary arrest: A small number of patients, particularly those receiving Erbitux with radiation and platinum based chemotherapy for head and neck cancer, have experienced serious heart and lung complications during treatment.
• Interstitial lung disease: New or worsening shortness of breath and cough during treatment should be reported to the oncology team right away, as this can signal lung inflammation.
• RAS mutation testing required: This medicine should not be used in colorectal cancer with certain RAS gene mutations, since it may not work and could worsen outcomes in that group.
• Pregnancy and fertility: This medicine may harm an unborn baby, so effective contraception is advised during treatment and for a period after the last dose, and breastfeeding is not recommended during this time.

Side Effects

Most patients on Erbitux experience some skin related side effects, especially during the first few weeks of treatment.

• Acne like rash on the face, chest, or back
• Dry, cracked, or itchy skin
• Changes in the nails or skin around the nails
• Tiredness and mild fever after infusion
• Diarrhea, nausea, or mouth sores

Some side effects need urgent medical attention and should never be managed at home.

• Sudden difficulty breathing, chest tightness, or swelling of the face and throat
• Signs of a serious lung problem, such as a new persistent cough or worsening shortness of breath
• Irregular heartbeat, severe dizziness, or fainting during or after infusion
• Very low magnesium or potassium levels, which can cause muscle cramps or weakness

Storage Conditions

Store in a refrigerator between 2 and 8 degrees Celsius, away from light and freezing temperatures, and never shake the vial. Keep the vial in its original carton until a healthcare professional is ready to prepare the dose, since this is a hospital administered medicine that is not stored or handled by patients at home.